Stockreport

Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncolo [Read more]